Clinical studies with SGLT2 inhibitors have reported reductions in fasting plasma glucose and glycated hemoglobin (HbA1c) levels (0.7–0.8%) compared to placebo and other glucose lowering strategies7, 8, 9, 10, 11, and a reduction in cardiovascular mortality in individuals with type 2 diabetes and high cardiovascular risk12. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.